A once-weekly 39-amino-acid dual agonist of the GIP and GLP-1 receptors (CAS 2023788-19-2). Built on a GIP peptide backbone with a C-20 fatty-diacid acylation for albumin binding. The GIP component amplifies GLP-1-driven insulinotropic and weight-loss effects while attenuating nausea. FDA-approved by Eli Lilly as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnea in adults with obesity).
For research purposes only. Not medical advice.
Crownwell Research currently lists Tirzepatide at $0.98/mg, the lowest indexed price across 19 tracked research peptide vendors.
Tirzepatide ranges from $0.97/mg to $9.90/mg across 92 listings from 19 research peptide vendors, normalized to USD per milligram and refreshed daily.
19 research peptide vendors currently list Tirzepatide on PeptideScouter, with 18 in stock right now. We track 92 active listings across size and kit variants.
Tirzepatide's CAS Registry Number is 2023788-19-2. It is also sold as GLP2-T, TRZ-2, T-GLP2.